• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:谢圣芳,盛梅笑,姚源璋,盖丰丰,王苏伟,王寒冰.肾宁Ⅱ号方治疗慢性肾脏病2~5期疗效观察[J].中国现代应用药学,2019,36(7):859-863.
XIE Shengfang,SHENG Meixiao,YAO Yuanzhang,GE Fengfeng,WANG Suwei,WANG Hanbing.Effect Observation of Shenning Ⅱ Decoction in the Treatment of Chronic Kidney Disease of Phase 2-5[J].Chin J Mod Appl Pharm(中国现代应用药学),2019,36(7):859-863.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2081次   下载 1065 本文二维码信息
码上扫一扫!
分享到: 微信 更多
肾宁Ⅱ号方治疗慢性肾脏病2~5期疗效观察
谢圣芳1, 盛梅笑2, 姚源璋1, 盖丰丰1, 王苏伟3, 王寒冰3
1.南京中医药大学附属中西医结合医院肾科, 南京 210028;2.南京中医药大学附属医院肾科, 南京 210029;3.南京中医药大学, 南京 210023
摘要:
目的 通过病例回顾性分析,观察肾宁Ⅱ号方治疗慢性肾脏病(chronic kidney disease,CKD)2~5期对近、远期肾功能影响。方法 共198例患者纳入观察,治疗组124例(肾宁Ⅱ号方加基础治疗),对照组74例(基础治疗)。观察治疗2周时2组患者肾功能、血尿酸及肝功能等实验室指标的变化,其中82例患者(治疗组59例、对照组23例)继续治疗并随访3个月,通过血肌酐倒数(1/Scr)随时间(月)直线回归斜率b值观察远期肾功能的变化趋势,并从理论上预测3年内进入终末期肾衰(end-stage renal failure,ESRD)患者的例数。结果 近期疗效,治疗组总有效率优于对照组(66.94% vs 51.35%,P<0.05),CKD 5期及非糖尿病肾病(non-diabetic kidney disease,NDKD)患者治疗组疗效优于对照组(67.44% vs 39.13%,71.43% vs 53.49%,P<0.05)。远期疗效,治疗组b值>对照组,b值正值数>对照组,预测治疗后3年内进入ESRD患者例数低于对照组,差异均有统计学意义(P<0.05)。结论 在常规治疗基础上,应用肾宁Ⅱ号方治疗CKD 2~5期患者有助于改善NDKD患者近期肾功能,并能够延缓肾功能不全病情进展。
关键词:  慢性肾脏病  肾宁Ⅱ号  临床疗效
DOI:10.13748/j.cnki.issn1007-7693.2019.07.018
分类号:R969.4
基金项目:江苏省中医药局课题资助项目(FY201510);第三批江苏省中医临床优秀人才研修项目(苏中医科教[2017]18号)
Effect Observation of Shenning Ⅱ Decoction in the Treatment of Chronic Kidney Disease of Phase 2-5
XIE Shengfang1, SHENG Meixiao2, YAO Yuanzhang1, GE Fengfeng1, WANG Suwei3, WANG Hanbing3
1.Department of Nephrology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China;2.Department of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China;3.Nanjing University of Chinese Medicine, Nanjing 210023, China
Abstract:
OBJECTIVE To observe the short-term and long-term clinical effect of Shenning Ⅱ decoction in the treatment of chronic kidney disease(CKD) of phase 2-5 by retrospective analysis method. METHODS A total of 198 patients were included in the study, 124 cases in the treatment group(received Shenning Ⅱ decoction and basic treatment) and 74 cases in the control group(received basic treatment). The change of renal function, serum uric acid and liver function in 2 groups were observed at 2 weeks after treatment. Eighty-two patients(59 cases in treatment group, 23 cases in control group) were continued treatment and followed up for 3 months, and the trend of renal function was observed by linear regression of slope b of reciprocal serum creatinine(1/Scr) with time(month), and the number of patients with end-stage renal failure(ESRD) in 3 years was predicted theoretically. RESULTS The total effective rate of the treatment group was higher than the control group(66.94% vs 51.35%, P<0.05), the total effective rate of patients of CKD5 and patients of non-diabetic kidney disease(NDKD) in the treatment group was higher than that of the control group(67.44% vs 39.13%, 71.43% vs 53.49%, P<0.05). About the long-term curative effect, the treatment group b value was higher than that of the control group, the number of positive b value of the treatment group was higher than the control group, the number of cases with ESRD predicted in the 3 year was less than that in the control group. The long-term curative effect is better in the treatment group(P<0.05). CONCLUSION On the basis of routine treatment, the Shenning Ⅱ decoction can improve renal function of CKD of phase 2-5 with NDKD patients and delay the progression of renal failure patients.
Key words:  chronic kidney disease  Shenning Ⅱ decoction  clinical effects
扫一扫关注本刊微信